AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer
Question
AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer
Direct answer
AstraZeneca submitted a New Drug Application to the US Food and Drug Administration for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib). The submission focuses on patients diagnosed with MET-driven, EGFR-mutated non-small cell lung cancer who have experienced disease progression following EGFR-TKI therapy. The regulatory filing represents an advance for HUTCHMED's targeted oncology pipeline in the United States and provides AstraZeneca an established combination pathway to treat secondary resistance mechanisms in its oncology franchise. — bullish pressure on AZN.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-29
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer”, revision 1, evidence through 2026-09-29. https://marketontology.com/catalysts/2026-09-29/astrazeneca-submits-us-nda-for-savolitinib-and-tagrisso-in-met-driven-lung-cance-902eaa
AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer
AstraZeneca submitted a New Drug Application to the US Food and Drug Administration for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib). The submission focuses on patients diagnosed with MET-driven, EGFR-mutated non-small cell lung cancer who have experienced disease progression following EGFR-TKI therapy. The regulatory filing represents an advance for HUTCHMED's targeted oncology pipeline in the United States and provides AstraZeneca an established combination pathway to treat secondary resistance mechanisms in its oncology franchise. — bullish pressure on AZN.
AstraZeneca submitted a New Drug Application to the US Food and Drug Administration for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib). The submission focuses on patients diagnosed with MET-driven, EGFR-mutated non-small cell lung cancer who have experienced disease progression following EGFR-TKI therapy. The regulatory filing represents an advance for HUTCHMED's targeted oncology pipeline in the United States and provides AstraZeneca an established combination pathway to treat secondary resistance mechanisms in its oncology franchise.
- SummaryAstraZeneca submitted a New Drug Application to the US Food and Drug Administration for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib). The submission focuses on patients diagnosed with MET-driven, EGFR-mutated non-small cell lung cancer who have experienced disease progression following EGFR-TKI therapy. The regulatory filing represents an advance for HUTCHMED's targeted oncology pipeline in the United States and provides AstraZeneca an established combination pathway to treat secondary resistance mechanisms in its oncology franchise.
- AZNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- AZN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- AZN price vs. pre-event level
- AZN volume vs. 20-day average
AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer
AstraZeneca submitted a New Drug Application to the US Food and Drug Administration for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib). The submission focuses on patients diagnosed with MET-driven, EGFR-mutated non-small cell lung cancer who have experienced disease progression following EGFR-TKI therapy. The regulatory filing represents an advance for HUTCHMED's targeted oncology pipeline in the United States and provides AstraZeneca an established combination pathway to treat secondary resistance mechanisms in its oncology franchise. — bullish pressure on HCM.
AstraZeneca submitted a New Drug Application to the US Food and Drug Administration for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib). The submission focuses on patients diagnosed with MET-driven, EGFR-mutated non-small cell lung cancer who have experienced disease progression following EGFR-TKI therapy. The regulatory filing represents an advance for HUTCHMED's targeted oncology pipeline in the United States and provides AstraZeneca an established combination pathway to treat secondary resistance mechanisms in its oncology franchise.
- SummaryAstraZeneca submitted a New Drug Application to the US Food and Drug Administration for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib). The submission focuses on patients diagnosed with MET-driven, EGFR-mutated non-small cell lung cancer who have experienced disease progression following EGFR-TKI therapy. The regulatory filing represents an advance for HUTCHMED's targeted oncology pipeline in the United States and provides AstraZeneca an established combination pathway to treat secondary resistance mechanisms in its oncology franchise.
- HCMDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- HCM closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- HCM price vs. pre-event level
- HCM volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| HCM | Bullishagreed | 14.15 2026-09-29 | +3.39% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.